Tenon Medical Inc Dossier
Qualitative Analysis
Business overview
Tenon Medical, Inc. (NASDAQ: TNON) is a medical device company founded in 2012 and headquartered in Los Gatos, California. The company is dedicated to developing and commercializing innovative, minimally invasive surgical solutions for patients suffering from chronic sacroiliac (SI) joint pain and dysfunction. Tenon's core commercial portfolio features the Catamaran® and SImmetry+® SI Joint Fusion Systems. The Catamaran system utilizes a patented inferior-posterior approach to place a single, robust titanium implant across the SI joint, transfixing it along its longitudinal axis. The SImmetry+ system, acquired to expand the company's clinical reach, offers a minimally invasive lateral access approach. Together, these platforms position Tenon to address primary SI joint fusions, revision procedures of failed implants, and SI joint fusion as an adjunct to multi-segment spinal fusion constructs.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning from a single-product company to a multi-product, multi-approach organization by combining the Catamaran platform with the newly acquired SImmetry and SImmetry+ lateral SI joint fusion systems.
Expected impact: Enables physicians to customize treatment plans based on variable patient anatomy, driving adoption, increasing procedure volumes, and capturing a larger market share.
Expanding the direct sales force and highly engaged distributor networks to maximize market penetration in strategic regions.
Expected impact: Accelerates adoption of the Catamaran and SImmetry platforms among spine surgeons and neurosurgeons.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of SImmetry and SImmetry+ technologies to expand Tenon's sacroiliac joint fusion portfolio across multiple surgical approaches, transforming the company into a multi-product sacro-pelvic organization.
Financial impact: Contributed immediately to revenue, with the first full quarter of contributions reflected in Q1 2026, driving a 90% year-over-year revenue increase.